Pneumonia · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Exacerbations · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Symptoms of dyspnoea · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes adverse events: candidiasis compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
Beclometasone showed no clear difference in withdrawal (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
It is very uncertain whether beclometasone/LABA changes mortality (all‐cause) (dichotomous Peto method) compared with LABA (very low certainty).
1 finding from 1 review
Pneumonia · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in pneumonia: participants with at least one (dichotomous Peto odds… compared with LABA (low certainty).
1 finding from 1 review
Exacerbations · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in exacerbations: participants with at least one (dichotomous) compared with LABA (moderate certainty).
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in withdrawal (all‐cause) compared with LABA (moderate certainty).
1 finding from 1 review
FEV1 · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes mortality (all‐cause) (dichotomous Peto method) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients with COPD
The intervention showed no clear difference in mortality (low certainty).
1 finding from 1 review
Intervention not reported
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · patients with COPD
1 finding from 1 review
Intervention not reported
Hospitalisation · patients with COPD
The intervention showed no clear difference in hospitalisation (low certainty).
1 finding from 1 review
Intervention not reported
Readmission to hospital, inpatient. Number of people experiencing one or more readmissions ( · exacerbations of COPD
The intervention probably leads to lower readmission to hospital, inpatient. Number of people experiencing… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality ( · exacerbations of COPD
The intervention showed no clear difference in mortality ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Patient satisfaction Number of people stating to be very satisfied with treatment ( · exacerbations of COPD
The intervention showed no clear difference in patient satisfaction Number of people stating to be very satisfied… (low certainty).
1 finding from 1 review
Intervention not reported
Carer satisfaction Number of carers stating to be very satisfied with treatment ( · exacerbations of COPD
It is very uncertain whether the intervention changes carer satisfaction Number of carers stating to be very satisfied… (very low certainty).
1 finding from 1 review